What the FDA labels say about taking them together
Gemfibrozil and pitavastatin
Gemfibrozil's FDA label of April 10, 2026 names pitavastatin in its drug interactions section, and pitavastatin's label names gemfibrozil too. The pitavastatin label: “Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including LIVALO.”
Check it at the source: the gemfibrozil FDA label on DailyMed (effective April 10, 2026, Northstar RxLLC); the pitavastatin FDA label on DailyMed (effective March 31, 2026, Kowa Pharmaceuticals America, Inc.).
What does the gemfibrozil label say about pitavastatin?
Gemfibrozil label, drug interactions(D) OATP1B1 substrates: Gemfibrozil is an inhibitor of OATP1B1 transporter and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan).
Source: FDA drug label (Gemfibrozil), Northstar RxLLC, effective April 10, 2026 (SPL set 75cac02c-56e3-4dfe-b1e2-4ce166b28833), via openFDA; the full label on DailyMed
What does the pitavastatin label say about gemfibrozil?
Pitavastatin label, drug interactionsClinical Impact: Gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with statins, including LIVALO. Intervention: Avoid concomitant use of gemfibrozil with LIVALO.
Pitavastatin label, warnings and precautionsSteps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis LIVALO is contraindicated in patients taking cyclosporine and not recommended in patients taking gemfibrozil [see Contraindications (4) and Drug Interactions (7) ].
Source: FDA drug label (Zypitamag, NDA208379), Medicure International Inc, effective December 3, 2025 (SPL set c8c50e03-5cb8-43f4-bdef-8edd12f1945f), via openFDA
Source: FDA drug label (Livalo), Kowa Pharmaceuticals America, Inc., effective March 31, 2026 (SPL set 44dcbf97-99ec-427c-ba50-207e0069d6d2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Gemfibrozil | Pitavastatin | |
|---|---|---|
| Labeled for | High cholesterol, Heart attack and coronary artery disease | High cholesterol |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.104 per tablet 600 mg tablet | $0.954 per tablet 2 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once